Sunesis gets EMA acceptance of Pediatric Investigation Plan for Qinprezo to treat AML
Currently, the company is carrying out a randomized, double-blind, placebo-controlled Phase III clinical trial (VALOR), in patients with first relapsed or refractory acute myeloid leukemia (AML). A PIP
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.